March 9, 2010
|
 |
Treatment Interruptions “Particularly Hazardous” for Those Coinfected With Hep B
Interrupting antiretroviral (ARV) therapy may be “particularly hazardous” for people living with HIV and chronic hepatitis B virus (HBV) infection, according to data from the Strategies for the Management of Antiretroviral Therapy (SMART) study published online by the journal AIDS. Increases in HBV viral load and accelerated immune deficiency were documented among coinfected individuals partaking in structured drug holidays in the study.
|
 |
|
 |
HIV and the Brain: Part 2
At the 17th Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco—David Evans speaks with Scott Letendre, MD, from the University of California in San Diego, about the relationship of HIV levels in the brain versus the blood, and what that might mean for treating HIV.
|
 |
|
 |
New Treatments for HIV: Part 1
At the 17th
Conference on Retroviruses and Opportunistic Infections (CROI) in San
Francisco—Tim Horn speaks with David Hardy, MD, from Cedars Sinai
Medical Center in Los Angeles, about new HIV treatments—including the
drug blood level-booster, cobicistat, and the new integrase inhibitor,
elvitegravir. Part 1 of a 2-part video.
|
 |
|
< Treatment News END -->
|
|
Subscribe
to the magazine now!
Featured Link
AIDSmeds Blogs
POZ
online:
News & Views
HIV
101
Connections
POZ
In Print
Direct
To Editors
POZ Personals
POZ Mentor
POZ ASO
Directory
AIDSmeds Blogs
AIDSmeds Forums
Graph
My Labs
Check
My Meds
|